Efficacy and Safety of Apatinib in Treating Advanced Colorectal Cancer.
10.3881/j.issn.1000-503X.10376
- Author:
Ning Ning LI
1
;
Jian Feng ZHOU
1
;
Lin ZHAO
1
;
Hong Yan YING
1
;
Ning JIA
1
Author Information
1. Department of Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100032,China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
adverse effects;
therapeutic use;
Colorectal Neoplasms;
drug therapy;
Humans;
Pyridines;
adverse effects;
therapeutic use;
Retrospective Studies;
Survival Analysis
- From:
Acta Academiae Medicinae Sinicae
2019;41(2):170-174
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and safety of apatinib in the treatment of advanced colorectal cancer(CRC). Methods The clinical data of 16 CRC patients treated with apatinib after failure of prior lines of treatment were retrospectively analyzed in terms of objective response rate,disease control rate,progression-free survival,overall survival,adverse events,and prognostic factors. Results The efficacy was evaluable in 14 patients,among whom the objective response rate was 7.1% and the disease control rate was 50%.The median progression-free survival was 3 months(95%CI=1.57-4.42),and the median overall survival was 6.5 months(95%CI=4.10-8.89).The safety was evaluable in 16 patients,among whom the most common grade 3 adverse events were hypertensinon(37.5%)and proteinuria(25%).No grade 4 adverse event was observed.Multivariate analysis did not show any factor directly related to survival.Conclusion Apatinib may be effective in treating advanced CRC,with tolerable side effects.
